Hot Investor Mandate: China-Based Biotech Company Seeking Global In-Licensing Opportunities in Oncology Indications with Potential for China Market

11 Oct

A biotech company founded in 2016 with several offices in China is VC backed with $150M Series A funding followed by $260 MM Series B funding. With immuno-oncology as the firm’s core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy. The company has a rich developing pipeline of oncology assets and is currently seeking in-licensing and partnership opportunities globally. The firm can invest in both private and public companies, depending on development stage of assets. The firm’s investment size depends on applicable deals.

The firm is particularly interested in first in class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy. The firm is currently focused on opportunities for the greater China market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: